GlassScriptPhysician profile
Ann Mcneill
NPI 1396973897
$371,858.46
in general payments reported to CMS, 2019-2025
29 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Oncology (Registered Nurse) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76K · 2022: $117K · 2023: $93K · 2024: $45K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Travel and Lodging: $56K · Food and Beverage: $8,757 · Honoraria: $7,500 · Consulting Fee: $2,272 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500 · Grant: $500 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,526.50 |
| Travel and Lodging | $55,828.03 |
| Food and Beverage | $8,757.23 |
| Honoraria | $7,500.00 |
| Consulting Fee | $2,271.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
| Grant | $500.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72,670.38 | 2021-2025 | |
| Seagen INC. | $68,870.29 | 2021-2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $61,355.06 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $53,896.45 | 2021-2025 | Kyprolis, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $35,959.15 | 2021-2023 | Pomalyst |
| Karyopharm Therapeutics INC. | $31,181.31 | 2021-2025 | Xpovio |
| Janssen Biotech, INC. | $22,238.71 | 2021-2024 | Imbruvica, Tecvayli, Darzalex |
| Incyte Corporation | $14,430.10 | 2021-2025 | Niktimvo, Niktimvo, Jakafi |
| Celgene Corporation | $5,349.23 | 2021-2025 | Breyanzi, Reblozyl |
| Genzyme Corporation | $4,299.23 | 2023-2024 | |
| Abbvie INC. | $364.27 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.42 | 2022-2024 | Ninlaro |
| Genentech USA, INC. | $166.02 | 2023-2025 | Venclexta |
| Daiichi Sankyo INC. | $152.19 | 2023-2025 | Vanflyta, Enhertu |
| Sanofi-Aventis U.S. LLC | $126.28 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $100.02 | 2025 | Carvykti |
| Taiho Oncology, INC. | $98.29 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $68.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.16 | 2025 | |
| Astellas Pharma US INC | $57.55 | 2025 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $43.65 | 2023 | Imfinzi, Lynparza |
| Janssen Scientific Affairs, LLC | $42.74 | 2022 | |
| Merck Sharp & Dohme LLC | $35.74 | 2023-2024 | Keytruda |
| Acrotech Biopharma INC. | $28.89 | 2022 | |
| Pharmacosmos Therapeutics INC. | $22.44 | 2024 | Monoferric |
| Cti Biopharma Corp. | $19.25 | 2023 | Vonjo |
| Cumberland Pharmaceuticals, INC. | $18.35 | 2025 | Sancuso |
| Kite Pharma, INC. | $16.99 | 2025 | Yescarta |
| Lilly USA, LLC | $14.33 | 2025 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Mcneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.